Clinical Trial Update: Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bendamustine and rituximab for splenic marginal zone lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone B-cell Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Marginal Zone B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-02-01